<p>懷俄明州在最近向證券交易委員會的披露中表示，在第四季度將其在輝瑞公司（NYSE:PFE - 免費報告）的持股增加了 293.0%。該基金在季度內購買了額外的 16,652 股後，持有 22,335 股這家生物製藥公司的股票。根據最近向證券交易委員會的備案，懷俄明州在輝瑞的持股價值為 593,000 美元。</p>
<ul>
<li>3 只高收益分紅股票，可能在 52 周低點附近反彈</li>
</ul>
<p>其他幾家機構投資者也最近增加或減少了在該公司的股份。Tallon Kerry Patrick 在第四季度購買了價值約 509,000 美元的輝瑞新股份。Merit Financial Group LLC 在第四季度將其在輝瑞的持股增加了 60.8%。Merit Financial Group LLC 現在擁有 127,967 股這家生物製藥公司的股票，價值 3,395,000 美元，此前在該期間內又購買了 48,397 股。Sax Wealth Advisors LLC 在第四季度將其在輝瑞的持股增加了 17.4%。Sax Wealth Advisors LLC 現在擁有 10,995 股這家生物製藥公司的股票，價值 292,000 美元，此前在該期間內又購買了 1,630 股。Lake Street Private Wealth LLC 在第四季度將其在輝瑞的持股增加了 8.3%。Lake Street Private Wealth LLC 現在擁有 10,096 股這家生物製藥公司的股票，價值 268,000 美元，此前在該期間內又購買了 776 股。最後，Ameritas Advisory Services LLC 在第四季度將其在輝瑞的持股增加了 3.6%。Ameritas Advisory Services LLC 現在擁有 75,983 股這家生物製藥公司的股票，價值 2,016,000 美元，此前在該期間內又購買了 2,633 股。目前 68.36% 的股票由機構投資者和對沖基金持有。</p>
<h2>輝瑞股價上漲 1.0%</h2>
<p>輝瑞（NYSE PFE）週一開盤價為 22.83 美元。該股票的 50 日移動平均價格為 23.65 美元，200 日移動平均價格為 25.32 美元。輝瑞公司的 52 周低點為 20.92 美元，52 周高點為 31.54 美元。該股票的市值為 1,297.7 億美元，市盈率為 16.19，市盈增長比率為 0.64，貝塔值為 0.58。該公司的速動比率為 0.73，流動比率為 1.00，債務與股本比率為 0.63。</p>
<ul>
<li>2 只醫療保健股票值得關注，因為摩根大通提升了吉利德的評級</li>
</ul>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 4 月 29 日（星期二）公佈了季度財報。這家生物製藥公司報告的每股收益（EPS）為 0.92 美元，超出市場普遍預期的 0.67 美元，超出幅度為 0.25 美元。輝瑞的股本回報率為 19.47%，淨利潤率為 12.62%。該公司在本季度的收入為 137.2 億美元，而分析師的預期為 144.3 億美元。在去年同期，該公司每股收益為 0.82 美元。輝瑞本季度的收入較去年同期下降了 7.8%。分析師預計輝瑞公司在當前財政年度的每股收益將達到 2.95 美元。</p>
<h2>輝瑞宣佈分紅</h2>
<p>該公司還最近披露了季度分紅，將於 6 月 13 日（星期五）支付。5 月 9 日（星期五）的股東將獲得每股 0.43 美元的分紅。這相當於每年 1.72 美元的分紅，收益率為 7.54%。除息日為 5 月 9 日（星期五）。輝瑞的派息比率目前為 124.64%。</p>
<h2>華爾街分析師的看法</h2>
<ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
<p>幾位股票研究分析師最近對該公司發表了看法。滙豐全球研究在 3 月 10 日（星期一）的研究報告中將輝瑞的評級提升至 “強力買入”。Cantor Fitzgerald 在 4 月 22 日（星期二）的研究報告中開始覆蓋輝瑞，給予 “中性” 評級和 24.00 美元的目標價。高盛集團在 4 月 8 日（星期二）的研究報告中重申了輝瑞的 “中性” 評級，並將目標價下調至 25.00 美元（之前為 32.00 美元）。Guggenheim 在 3 月 18 日（星期二）的報告中重申了輝瑞的 “買入” 評級。最後，瑞銀集團在 4 月 30 日（星期三）的報告中將輝瑞的目標價從 24.00 美元提高至 25.00 美元，並給予該公司 “中性” 評級。一位研究分析師對該股票給予了賣出評級，八位給予持有評級，四位給予買入評級，三位給予強力買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 29.17 美元。</p>
<p><strong>閲讀我們關於輝瑞的最新報告</strong></p>
<h2>輝瑞公司簡介</h2>
<p>（免費報告）</p>
<p>輝瑞公司在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；針對未滿足醫療需求的傳染病，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及未來潛在的 mRNA 和抗病毒產品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過輝瑞</li>
<li>安靜期到期的解釋</li>
<li>Nextracker 的太陽能激增：它會打破歷史最高紀錄嗎？</li>
<li>內部人士出售的解釋：它能否為你的投資選擇提供信息？</li>
<li>精明的投資者為喜力股票舉杯慶祝</li>
<li>什麼是日經 225 指數？</li>
<li>關税減免後，中國投資的四大 ETF</li>
</ul>
<p><strong>想看看其他對沖基金持有的 PFE 嗎？</strong> 訪問 HoldingsChannel.com，獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 備案和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>這條即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

<p>懷俄明州在第四季度將其在輝瑞公司（NYSE:PFE）的持股增加了 293%，目前持有 22,335 股，價值 593,000 美元。其他機構投資者也增加了他們的持股。輝瑞的股票開盤價為 22.83 美元，市值為 1297.7 億美元。公司報告第一季度每股收益為 0.92 美元，超出預期，但收入同比下降了 7.8%。輝瑞宣佈每股季度分紅為 0.43 美元，收益率為 7.54%。分析師的評級意見不一，普遍評級為 “適度買入”，平均目標價為 29.17 美元</p>

<p>State of Wyoming boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 293.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,335 shares of the biopharmaceutical company's stock after purchasing an additional 16,652 shares during the quarter. State of Wyoming's holdings in Pfizer were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>懷俄明州在最近向證券交易委員會的披露中表示，在第四季度將其在輝瑞公司（NYSE:PFE - 免費報告）的持股增加了 293.0%。該基金在季度內購買了額外的 16,652 股後，持有 22,335 股這家生物製藥公司的股票。根據最近向證券交易委員會的備案，懷俄明州在輝瑞的持股價值為 593,000 美元。</p>
</div><ul>
<li>3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高收益分紅股票，可能在 52 周低點附近反彈</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in the business. Tallon Kerry Patrick purchased a new stake in Pfizer during the fourth quarter valued at about $509,000. Merit Financial Group LLC grew its position in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after acquiring an additional 48,397 shares during the period. Sax Wealth Advisors LLC grew its position in Pfizer by 17.4% during the fourth quarter. Sax Wealth Advisors LLC now owns 10,995 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 1,630 shares during the period. Lake Street Private Wealth LLC grew its position in Pfizer by 8.3% during the fourth quarter. Lake Street Private Wealth LLC now owns 10,096 shares of the biopharmaceutical company's stock valued at $268,000 after acquiring an additional 776 shares during the period. Finally, Ameritas Advisory Services LLC grew its position in Pfizer by 3.6% during the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company's stock valued at $2,016,000 after acquiring an additional 2,633 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者也最近增加或減少了在該公司的股份。Tallon Kerry Patrick 在第四季度購買了價值約 509,000 美元的輝瑞新股份。Merit Financial Group LLC 在第四季度將其在輝瑞的持股增加了 60.8%。Merit Financial Group LLC 現在擁有 127,967 股這家生物製藥公司的股票，價值 3,395,000 美元，此前在該期間內又購買了 48,397 股。Sax Wealth Advisors LLC 在第四季度將其在輝瑞的持股增加了 17.4%。Sax Wealth Advisors LLC 現在擁有 10,995 股這家生物製藥公司的股票，價值 292,000 美元，此前在該期間內又購買了 1,630 股。Lake Street Private Wealth LLC 在第四季度將其在輝瑞的持股增加了 8.3%。Lake Street Private Wealth LLC 現在擁有 10,096 股這家生物製藥公司的股票，價值 268,000 美元，此前在該期間內又購買了 776 股。最後，Ameritas Advisory Services LLC 在第四季度將其在輝瑞的持股增加了 3.6%。Ameritas Advisory Services LLC 現在擁有 75,983 股這家生物製藥公司的股票，價值 2,016,000 美元，此前在該期間內又購買了 2,633 股。目前 68.36% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Pfizer Trading Up 1.0%</h2>
<div class="lb-trans"><h2>輝瑞股價上漲 1.0%</h2>
</div><p>Shares of NYSE PFE opened at $22.83 on Monday. The stock's 50 day moving average price is $23.65 and its two-hundred day moving average price is $25.32. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.</p>
<div class="lb-trans"><p>輝瑞（NYSE PFE）週一開盤價為 22.83 美元。該股票的 50 日移動平均價格為 23.65 美元，200 日移動平均價格為 25.32 美元。輝瑞公司的 52 周低點為 20.92 美元，52 周高點為 31.54 美元。該股票的市值為 1,297.7 億美元，市盈率為 16.19，市盈增長比率為 0.64，貝塔值為 0.58。該公司的速動比率為 0.73，流動比率為 1.00，債務與股本比率為 0.63。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只醫療保健股票值得關注，因為摩根大通提升了吉利德的評級</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 4 月 29 日（星期二）公佈了季度財報。這家生物製藥公司報告的每股收益（EPS）為 0.92 美元，超出市場普遍預期的 0.67 美元，超出幅度為 0.25 美元。輝瑞的股本回報率為 19.47%，淨利潤率為 12.62%。該公司在本季度的收入為 137.2 億美元，而分析師的預期為 144.3 億美元。在去年同期，該公司每股收益為 0.82 美元。輝瑞本季度的收入較去年同期下降了 7.8%。分析師預計輝瑞公司在當前財政年度的每股收益將達到 2.95 美元。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>輝瑞宣佈分紅</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.</p>
<div class="lb-trans"><p>該公司還最近披露了季度分紅，將於 6 月 13 日（星期五）支付。5 月 9 日（星期五）的股東將獲得每股 0.43 美元的分紅。這相當於每年 1.72 美元的分紅，收益率為 7.54%。除息日為 5 月 9 日（星期五）。輝瑞的派息比率目前為 124.64%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
</div><p>Several equities research analysts have recently weighed in on the company. Hsbc Global Res raised Pfizer to a &#34;strong-buy&#34; rating in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a &#34;neutral&#34; rating and a $24.00 target price for the company. The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reissued a &#34;buy&#34; rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $29.17.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了看法。滙豐全球研究在 3 月 10 日（星期一）的研究報告中將輝瑞的評級提升至 “強力買入”。Cantor Fitzgerald 在 4 月 22 日（星期二）的研究報告中開始覆蓋輝瑞，給予 “中性” 評級和 24.00 美元的目標價。高盛集團在 4 月 8 日（星期二）的研究報告中重申了輝瑞的 “中性” 評級，並將目標價下調至 25.00 美元（之前為 32.00 美元）。Guggenheim 在 3 月 18 日（星期二）的報告中重申了輝瑞的 “買入” 評級。最後，瑞銀集團在 4 月 30 日（星期三）的報告中將輝瑞的目標價從 24.00 美元提高至 25.00 美元，並給予該公司 “中性” 評級。一位研究分析師對該股票給予了賣出評級，八位給予持有評級，四位給予買入評級，三位給予強力買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 29.17 美元。</p>
</div><p><strong>Read Our Latest Report on Pfizer</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於輝瑞的最新報告</strong></p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>輝瑞公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>輝瑞公司在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；針對未滿足醫療需求的傳染病，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及未來潛在的 mRNA 和抗病毒產品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Quiet Period Expirations Explained</li>
<li>Nextracker’s Solar Surge: Will It Shatter Its All-Time High?</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Savvy Investors Are Raising a Glass for Heineken Stock</li>
<li>What is the Nikkei 225 index?</li>
<li>Top 4 ETFs for China Exposure After Tariff Relief</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過輝瑞</li>
<li>安靜期到期的解釋</li>
<li>Nextracker 的太陽能激增：它會打破歷史最高紀錄嗎？</li>
<li>內部人士出售的解釋：它能否為你的投資選擇提供信息？</li>
<li>精明的投資者為喜力股票舉杯慶祝</li>
<li>什麼是日經 225 指數？</li>
<li>關税減免後，中國投資的四大 ETF</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 PFE 嗎？</strong> 訪問 HoldingsChannel.com，獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 備案和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這條即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Pfizer Inc. (NYSE:PFE) Shares Bought by State of Wyoming

- 懷俄明州在第四季度將其在輝瑞公司的持股增加了 293.0%。
- 該州持有輝瑞 22,335 股，市值約為 593,000 美元。
- 68.36% 的輝瑞股票目前由機構投資者和對沖基金持有。

懷俄明州購買了輝瑞公司（NYSE:PFE）的股票